FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2990244722> ?p ?o ?g. }

• W2990244722 endingPage "32" @default.
• W2990244722 startingPage "22" @default.
• W2990244722 abstract "Abstract Purpose To examine the reporting rates of adverse drug events (ADEs) with apixaban and empagliflozin as reports move up to the next level of spontaneous reporting. Methods This was a retrospective cohort study of outpatients who discontinued apixaban or empagliflozin within 3 years of Food and Drug Administration (FDA) approval. We enriched the sample using an active surveillance strategy to identify subsets of patients with International Classification of Diseases (ICD) codes possibly associated with an ADE. Stratified random samples of charts were reviewed to determine if patients discontinued the medication due to an ADE. If so, we ascertained whether these were uploaded into the Veterans Administration (VA) electronic health record reporting system (Adverse Reaction Tracking System [ARTS]), VA national Web-based system (VA Adverse Drug Event Reporting System [VA ADERS]), and FDA MedWatch. Results From the cohort of 2,973 patients who discontinued apixaban, 321 patients (10.8%) were randomly sampled for chart review (including 61 patients with relevant ICD codes). During chart review, 88 ADEs were identified, with 40/61 (65.6%) from the subset with ICD codes. Of the total of 88 ADEs, 18.2%, 10.2%, and 6.8% were reported in ARTS, VA ADERS, and MedWatch, respectively. Of the 1,555 patients who discontinued empagliflozin, 179 patients (11.5%) were randomly sampled for chart review (40 patients with relevant ICD codes). During chart review, 78 ADEs were identified, with 19/40 (47.5%) from the subset with ICD codes. Of the 78 ADEs, 28.2%, 19.2%, and 7.7% were reported in ARTS, VA ADERS, and MedWatch, respectively. Conclusion We found substantial underreporting of apixaban and empagliflozin ADEs that became worse at each higher level of spontaneous reporting." @default.
• W2990244722 created "2019-12-05" @default.
• W2990244722 creator A5010577995 @default.
• W2990244722 creator A5012742878 @default.
• W2990244722 creator A5017141384 @default.
• W2990244722 creator A5029911127 @default.
• W2990244722 creator A5039605963 @default.
• W2990244722 creator A5055635095 @default.
• W2990244722 creator A5065875700 @default.
• W2990244722 date "2019-11-22" @default.
• W2990244722 modified "2023-09-27" @default.
• W2990244722 title "Reporting of adverse drug events in the Veterans Health Administration for patients whose treatment with empagliflozin or apixaban was discontinued" @default.
• W2990244722 cites W122320840 @default.
• W2990244722 cites W1494561330 @default.
• W2990244722 cites W1539403009 @default.
• W2990244722 cites W1586042412 @default.
• W2990244722 cites W177097020 @default.
• W2990244722 cites W1949215780 @default.
• W2990244722 cites W1963556263 @default.
• W2990244722 cites W1968832457 @default.
• W2990244722 cites W2009890917 @default.
• W2990244722 cites W2012609176 @default.
• W2990244722 cites W2015365539 @default.
• W2990244722 cites W2024754083 @default.
• W2990244722 cites W2030509703 @default.
• W2990244722 cites W2048865201 @default.
• W2990244722 cites W2061326496 @default.
• W2990244722 cites W2086032206 @default.
• W2990244722 cites W2109238714 @default.
• W2990244722 cites W2153972688 @default.
• W2990244722 cites W2164111356 @default.
• W2990244722 cites W2316129007 @default.
• W2990244722 cites W68214392 @default.
• W2990244722 cites W92929729 @default.
• W2990244722 doi "https://doi.org/10.1093/ajhp/zxz261" @default.
• W2990244722 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31756249" @default.
• W2990244722 hasPublicationYear "2019" @default.
• W2990244722 type Work @default.
• W2990244722 sameAs 2990244722 @default.
• W2990244722 citedByCount "3" @default.
• W2990244722 countsByYear W29902447222019 @default.
• W2990244722 countsByYear W29902447222022 @default.
• W2990244722 countsByYear W29902447222023 @default.
• W2990244722 crossrefType "journal-article" @default.
• W2990244722 hasAuthorship W2990244722A5010577995 @default.
• W2990244722 hasAuthorship W2990244722A5012742878 @default.
• W2990244722 hasAuthorship W2990244722A5017141384 @default.
• W2990244722 hasAuthorship W2990244722A5029911127 @default.
• W2990244722 hasAuthorship W2990244722A5039605963 @default.
• W2990244722 hasAuthorship W2990244722A5055635095 @default.
• W2990244722 hasAuthorship W2990244722A5065875700 @default.
• W2990244722 hasConcept C126322002 @default.
• W2990244722 hasConcept C134018914 @default.
• W2990244722 hasConcept C167135981 @default.
• W2990244722 hasConcept C194828623 @default.
• W2990244722 hasConcept C195910791 @default.
• W2990244722 hasConcept C197934379 @default.
• W2990244722 hasConcept C2775887513 @default.
• W2990244722 hasConcept C2775969662 @default.
• W2990244722 hasConcept C2776301958 @default.
• W2990244722 hasConcept C2778661090 @default.
• W2990244722 hasConcept C2779161974 @default.
• W2990244722 hasConcept C2780638905 @default.
• W2990244722 hasConcept C2910068830 @default.
• W2990244722 hasConcept C555293320 @default.
• W2990244722 hasConcept C71924100 @default.
• W2990244722 hasConcept C72563966 @default.
• W2990244722 hasConceptScore W2990244722C126322002 @default.
• W2990244722 hasConceptScore W2990244722C134018914 @default.
• W2990244722 hasConceptScore W2990244722C167135981 @default.
• W2990244722 hasConceptScore W2990244722C194828623 @default.
• W2990244722 hasConceptScore W2990244722C195910791 @default.
• W2990244722 hasConceptScore W2990244722C197934379 @default.
• W2990244722 hasConceptScore W2990244722C2775887513 @default.
• W2990244722 hasConceptScore W2990244722C2775969662 @default.
• W2990244722 hasConceptScore W2990244722C2776301958 @default.
• W2990244722 hasConceptScore W2990244722C2778661090 @default.
• W2990244722 hasConceptScore W2990244722C2779161974 @default.
• W2990244722 hasConceptScore W2990244722C2780638905 @default.
• W2990244722 hasConceptScore W2990244722C2910068830 @default.
• W2990244722 hasConceptScore W2990244722C555293320 @default.
• W2990244722 hasConceptScore W2990244722C71924100 @default.
• W2990244722 hasConceptScore W2990244722C72563966 @default.
• W2990244722 hasIssue "1" @default.
• W2990244722 hasLocation W29902447221 @default.
• W2990244722 hasLocation W29902447222 @default.
• W2990244722 hasOpenAccess W2990244722 @default.
• W2990244722 hasPrimaryLocation W29902447221 @default.
• W2990244722 hasRelatedWork W1506449882 @default.
• W2990244722 hasRelatedWork W1858716145 @default.
• W2990244722 hasRelatedWork W188059099 @default.
• W2990244722 hasRelatedWork W2001225302 @default.
• W2990244722 hasRelatedWork W2021599063 @default.
• W2990244722 hasRelatedWork W2127172625 @default.
• W2990244722 hasRelatedWork W2746504652 @default.
• W2990244722 hasRelatedWork W2793835639 @default.
• W2990244722 hasRelatedWork W3095549380 @default.
• W2990244722 hasRelatedWork W3209357632 @default.

• next